- Home
- ELVN
as 10-04-2024 4:00pm EST
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $34.33 | AVG Volume (30 days): | 309.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.80 - $27.67 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Enliven Therapeutics Inc. (ELVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Heyman Richard A. | ELVN | Director | Oct 1 '24 | Sell | $27.54 | 518 | $14,264.32 | 128,585 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | Oct 1 '24 | Sell | $27.54 | 526 | $14,484.51 | 1,048,729 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Aug 29 '24 | Sell | $22.78 | 12,000 | $269,841.39 | 1,077,936 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | Aug 26 '24 | Sell | $22.89 | 12,000 | $274,718.40 | 1,048,729 | |
| Heyman Richard A. | ELVN | Director | Aug 15 '24 | Sell | $23.26 | 1,270 | $29,526.20 | 128,585 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Jul 31 '24 | Sell | $27.56 | 3,099 | $85,399.45 | 1,077,936 | |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Jul 31 '24 | Sell | $27.53 | 991 | $27,280.94 | 0 | |
| Heyman Richard A. | ELVN | Director | Jul 31 '24 | Sell | $27.50 | 2,351 | $64,662.54 | 128,585 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | Jul 31 '24 | Sell | $27.56 | 2,270 | $62,555.07 | 1,048,729 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Jul 29 '24 | Sell | $27.06 | 12,000 | $320,377.80 | 1,077,936 |
Latest Enliven Therapeutics Inc. News
ELVN Breaking Stock News: Dive into ELVN Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
5 days ago
Enliven Therapeutics’ ELVN-001 shows promise in Phase I CML trial
GlobeNewswire
7 days ago
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Zacks
9 days ago
Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going
GlobeNewswire
17 days ago
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML
Benzinga
a month ago
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Zacks
a month ago
Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High?
MT Newswires
a month ago
Enliven Therapeutics Insider Sold Shares Worth $269,841, According to a Recent SEC Filing
Simply Wall St.
a month ago
Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans
Compare ELVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ELVN Enliven Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.